On November 4, 2016 Redx Pharma Plc reported that it will present the pre-clinical profile of its reversible Bruton’s tyrosine kinase (BTK) inhibitor at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on 5 December 2016 in San Diego, California (Press release, Redx Pharma, NOV 4, 2016, View Source [SID1234524712]). The compound, named RXC005 (also known as REDX08608), is a novel, potent and selective, reversible BTK inhibitor that is equipotent against wild-type and mutant C481S BTK. C481 mutant BTK protein is currently estimated to be responsible for around 60% of the observed Ibrutinib resistance in patients with chronic lymphocytic leukaemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.

The Abstract for the presentation is available on the ASH (Free ASH Whitepaper) Conference website:
View Source;

Dr Neil Murray, CEO of Redx, said: We’re delighted to present the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the prestigious American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December.

RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to Ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017.